Oncology is the leading therapeutic area. This dominance is driven by the molecular heterogeneity of cancer, the rise of immuno-oncology, and the increasing regulatory requirement for companion diagnostics to support targeted therapies.
Outsourcing allows sponsors to accelerate R&D timelines, reduce heavy infrastructure costs, and access specialized expertise in bioinformatics and high-throughput screening. It also provides the flexibility to shift research directions quickly based on interim clinical findings.
AI and ML are causing a paradigm shift by enabling the integration of massive datasets across genomics, proteomics, and metabolomics. These technologies allow outsourced partners to develop predictive models with higher accuracy, improving patient stratification in clinical trials.
Predictive biomarkers are the primary market driver as they help predict therapeutic outcomes and inform decisions on targeted therapies. Safety biomarkers are used for risk mitigation, helping developers monitor toxicity and side effects during preclinical and clinical programs.
North America, led by the United States, is the dominant region. Its leadership is attributed to a mature pharmaceutical ecosystem, a well-established network of Contract Research Organizations (CROs), high investment in precision medicine, and a strong regulatory focus on companion diagnostics.
The Asia-Pacific (APAC) region is the fastest-growing market. Growth is fueled by booming pharmaceutical manufacturing in China and India, increasing participation in global clinical trials, and government incentives designed to spur biotech innovation.
Regulatory bodies are increasingly requiring drugs—particularly in oncology—to be submitted alongside companion diagnostics. This strategic necessity pushes pharmaceutical companies to seek outsourced expertise to ensure compliance and achieve faster market clearance.
In 2024, Thermo Fisher Scientific expanded its multi-omics service suite; Charles River Laboratories collaborated with a major biotech firm to advance neurodegenerative biomarkers; and Quest Diagnostics established a global biomarker testing hub to standardize methodologies for multinational trials.
Significant opportunities include the development of AI-powered discovery platforms, the discovery of early-stage biomarkers for neurology (Alzheimer’s and Parkinson’s), the integration of multi-omics profiling, and the expansion of services into emerging APAC biopharma hubs.
